BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22432519)

  • 1. Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus.
    Meignan M; Gallamini A; Itti E; Barrington S; Haioun C; Polliack A
    Leuk Lymphoma; 2012 Oct; 53(10):1876-81. PubMed ID: 22432519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010.
    Meignan M; Gallamini A; Haioun C; Polliack A
    Leuk Lymphoma; 2010 Dec; 51(12):2171-80. PubMed ID: 21077737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012.
    Meignan M; Barrington S; Itti E; Gallamini A; Haioun C; Polliack A
    Leuk Lymphoma; 2014 Jan; 55(1):31-7. PubMed ID: 23763460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers.
    Biggi A; Gallamini A; Chauvie S; Hutchings M; Kostakoglu L; Gregianin M; Meignan M; Malkowski B; Hofman MS; Barrington SF
    J Nucl Med; 2013 May; 54(5):683-90. PubMed ID: 23516309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Report on the 5th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 19-20 September 2014.
    Meignan M; Gallamini A; Haioun C; Barrington S; Itti E; Luminari S; Polliack A
    Leuk Lymphoma; 2015 May; 56(5):1229-32. PubMed ID: 26086968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Report on the First International Workshop on Interim-PET-Scan in Lymphoma.
    Meignan M; Gallamini A; Meignan M; Gallamini A; Haioun C
    Leuk Lymphoma; 2009 Aug; 50(8):1257-60. PubMed ID: 19544140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.
    Safar V; Dupuis J; Itti E; Jardin F; Fruchart C; Bardet S; Véra P; Copie-Bergman C; Rahmouni A; Tilly H; Meignan M; Haioun C
    J Clin Oncol; 2012 Jan; 30(2):184-90. PubMed ID: 22162590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
    Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
    J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
    Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
    Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
    Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
    AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Staging and response assessment in lymphomas: the new Lugano classification.
    Cheson BD
    Chin Clin Oncol; 2015 Mar; 4(1):5. PubMed ID: 25841712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma.
    Nols N; Mounier N; Bouazza S; Lhommel R; Costantini S; Vander Borght T; Vekemans MC; Sonet A; Bosly A; Michaux L; André M; Van Den Neste E
    Leuk Lymphoma; 2014 Apr; 55(4):773-80. PubMed ID: 23927393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
    Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
    Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posttreatment PET/CT Rather Than Interim PET/CT Using Deauville Criteria Predicts Outcome in Pediatric Hodgkin Lymphoma: A Prospective Study Comparing PET/CT with Conventional Imaging.
    Bakhshi S; Bhethanabhotla S; Kumar R; Agarwal K; Sharma P; Thulkar S; Malhotra A; Dhawan D; Vishnubhatla S
    J Nucl Med; 2017 Apr; 58(4):577-583. PubMed ID: 27754902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.
    Agostinelli C; Gallamini A; Stracqualursi L; Agati P; Tripodo C; Fuligni F; Sista MT; Fanti S; Biggi A; Vitolo U; Rigacci L; Merli F; Patti C; Romano A; Levis A; Trentin L; Stelitano C; Borra A; Piccaluga PP; Hamilton-Dutoit S; Kamper P; Zaucha JM; Małkowski B; Kulikowski W; Tajer J; Subocz E; Rybka J; Steidl C; Broccoli A; Argnani L; Gascoyne RD; d'Amore F; Zinzani PL; Pileri SA
    Lancet Haematol; 2016 Oct; 3(10):e467-e479. PubMed ID: 27692305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Report of the 6th International Workshop on PET in lymphoma.
    Nanni C; Cottereau AS; Lopci E; Bodet-Milin C; Coronado M; Pro B; Kim WS; Trotman J; Barrington S; Duhrsen U; Vander Borght T; Zamagni E; Kraeber-Bodéré F; Messiou C; Rahmouni A; Buvat I; Andre M; Hertzberg M; Oyen W; Casasnovas O; Luminari S; Garderet L; Montravers F; Kobe C; Kluge R; Versari A; Zucca E; Moreau P; Cheson B; Haioun C; Gallamini A; Meignan M
    Leuk Lymphoma; 2017 Oct; 58(10):2298-2303. PubMed ID: 28264597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
    Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
    Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma.
    Shinya T; Fujii S; Asakura S; Taniguchi T; Yoshio K; Alafate A; Sato S; Yoshino T; Kanazawa S
    Ann Nucl Med; 2012 Oct; 26(8):616-21. PubMed ID: 22692457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG-PET for Early Response Assessment in Lymphomas: Part 2-Diffuse Large B-Cell Lymphoma, Use of Quantitative PET Evaluation.
    Cheson BD; Kostakoglu L
    Oncology (Williston Park); 2017 Jan; 31(1):71-76. PubMed ID: 28090627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative analysis of basal and interim PET/CT images for predicting tumor recurrence in patients with Hodgkin's lymphoma.
    Strigari L; Attili A; Duggento A; Chiaravalloti A; Schillaci O; Guerrisi MG
    Nucl Med Commun; 2016 Jan; 37(1):16-22. PubMed ID: 26440569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.